Stock 300485 BEIJING SCIENCE SUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Beijing Science Sun Pharmaceutical Co., Ltd.

Equities

300485

CNE100002110

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
7.27 CNY -0.68% Intraday chart for Beijing Science Sun Pharmaceutical Co., Ltd. -5.09% -31.35%
Apr. 26 Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million. CI
Apr. 25 Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million.
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for the Year 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Final Dividend for 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Lin Xuehua completed the acquisition of a 45% stake in Beijing Zhongrun Weiye Investment Co., Ltd. from Beijing Science Sun Pharmaceutical Co., Ltd. for CNY 6.6 million.
CI
Science Sun Pharma Passes Inspection of Premises
MT
Lin Xuehua intends to acquire 45% stake in Beijing Zhongrun Weiye Investment Co., Ltd. from Beijing Science Sun Pharmaceutical Co., Ltd. for CNY 6.65 million
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021
CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300485 Stock
  4. News Beijing Science Sun Pharmaceutical Co., Ltd.
  5. Highlights